OncoCyte Corp (STU:7OC0)
€ 3.34 0 (0%) Market Cap: 32.55 Mil Enterprise Value: 30.49 Mil PE Ratio: 0 PB Ratio: 1.89 GF Score: 32/100

OncoCyte Corp DetermalO™ and Tumor Microenvironment in Clinical Practice Key Opinion Leader Transcript

Jun 28, 2022 / 02:00PM GMT
Release Date Price: €16.9 (-9.63%)
Operator

Good morning, and welcome to the OncoCyte Expert Webinar. (Operator Instructions) As a reminder, this call is being recorded and a replay will be made available on the OncoCyte website following the conclusion of the event.

Before turning the call over to Doug Ross of OncoCyte, I would like to remind you that during this conference call, the company will make projections and forward-looking statements regarding future events. Any statements that are not historical fact are forward-looking statements. We encourage you to review the company's SEC filings, which identify the specific risk factors that may cause actual results or events to differ materially from those described in these forward-looking statements.

I'd now like to turn the call over to Dr. Doug Ross, Chief Scientific Officer of OncoCyte. Please go ahead, Doug.

Douglas T. Ross
OncoCyte Corporation - Chief Science Officer

Well, thank you all for joining us. I really appreciate your taking some time out of your day to learn about some of our latest developments of our product

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot